Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

2.

Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

3.

Why breast cancer survivors don't take their medicine, and what can be done about it.

4.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.

5.

Advanced breast cancer patients living longer thanks to improvements in treatment and care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot